Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N9YP
|
|||
| Former ID |
DIB020577
|
|||
| Drug Name |
NTE-1
|
|||
| Synonyms |
Methyl [(2s)-2-[4-({5-[4-({(2s)-2-[(3s)-3-Amino-2-Oxopiperidin-1-Yl]-2-Cyclohexylacetyl}amino)phenyl]pentyl}oxy)phenyl]-3-(Quinolin-3-Yl)propyl]carbamate; NTE-1; GTPL8596; 2Q6; methyl N-[(2S)-2-[4-[5-[4-[[(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl]amino]phenyl]pentoxy]phenyl]-3-quinolin-3-ylpropyl]carbamate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C44H55N5O5
|
|||
| Canonical SMILES |
COC(=O)NCC(CC1=CC2=CC=CC=C2N=C1)C3=CC=C(C=C3)OCCCCCC4=CC=C(C=C4)NC(=O)C(C5CCCCC5)N6CCCC(C6=O)N
|
|||
| InChI |
1S/C44H55N5O5/c1-53-44(52)47-30-36(28-32-27-35-14-7-8-16-40(35)46-29-32)33-19-23-38(24-20-33)54-26-9-3-4-11-31-17-21-37(22-18-31)48-42(50)41(34-12-5-2-6-13-34)49-25-10-15-39(45)43(49)51/h7-8,14,16-24,27,29,34,36,39,41H,2-6,9-13,15,25-26,28,30,45H2,1H3,(H,47,52)(H,48,50)/t36-,39+,41+/m1/s1
|
|||
| InChIKey |
IGRIVAWLJUPVMM-UDEWTJCRSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Insulin-degrading enzyme (IDE) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Alzheimer's disease | |||
| WikiPathways | Alzheimers Disease | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo. J Biol Chem. 2015 Aug 14;290(33):20044-59. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.